DOI QR코드

DOI QR Code

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-$M\ddot{u}llerian$ hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome

  • Chun, Sungwook (Department of Obstetrics and Gynecology, Inje University Haeundae Paik Hospital, Inje University College of Medicine)
  • 투고 : 2014.04.18
  • 심사 : 2014.06.02
  • 발행 : 2014.06.30

초록

Objective: The aim of the present study was to investigate the relationship between ovarian follicle count and volume on ultrasonography and serum hormone levels including the levels of the anti-$M\ddot{u}llerian$ hormone (AMH) and gonadotropin in women with the polycystic ovary syndrome (PCOS). Methods: A total of 118 Korean women aged 18-35 years who were newly diagnosed with PCOS at a university hospital were included in this study. Serum LH, FSH, and AMH levels were measured in the early follicular phase, and the total antral follicle count (TFC) and the total ovarian volume (TOV) were assessed by ultrasonography. The correlations between serum hormonal parameters and ultrasonography characteristics in women with PCOS were evaluated using Pearson's correlation coefficients and a linear regression analysis. Results: Serum AMH levels were significantly correlated with serum LH levels and LH/FSH ratios, and TFC and TOV were significantly correlated with each other on ultrasonography. Serum AMH and LH levels and the LH/FSH ratio were significantly correlated with TFC. Statistically significant correlations between TOV and the LH level (r=0.208, p=0.024) and the LH/FSH ratio (r=0.237, p=0.010) were observed. However, the serum AMH level was not significantly correlated with the ovarian volume, and this result did not change after adjusting for age and body mass index. Conclusion: Serum AMH is not related to the ovarian volume in women with PCOS. My results suggest that serum LH level and the LH/FSH ratio may be more useful than the serum AMH level for representing the status of the ovarian volume in women with PCOS.

키워드

참고문헌

  1. Kuzbari O, Doralis J, Peterson CM. Endocrine disorders. In: Berek JS, editor. Berek & Novak's gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 1075-80.
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  3. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003;18:598-603. https://doi.org/10.1093/humrep/deg115
  4. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-14. https://doi.org/10.1093/humupd/dmg044
  5. Buckett WM, Bouzayen R, Watkin KL, Tulandi T, Tan SL. Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod 1999;14:618-21. https://doi.org/10.1093/humrep/14.3.618
  6. Fritz MA, Speroff L, editors. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 501-18.
  7. Lee JR, Kim SH. Anti-Mullerian hormone and female reproduction. Korean J Obstet Gynecol 2009;52:285-300.
  8. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957-62. https://doi.org/10.1210/jc.2003-030727
  9. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318-23. https://doi.org/10.1210/jc.2003-030932
  10. La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970-2. https://doi.org/10.1016/j.fertnstert.2004.06.001
  11. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123-9. https://doi.org/10.1093/humrep/der297
  12. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012;27:2494-502. https://doi.org/10.1093/humrep/des213
  13. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332-40. https://doi.org/10.1210/jc.2013-1393
  14. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979-87. https://doi.org/10.1016/j.fertnstert.2004.11.029
  15. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-7. https://doi.org/10.1093/humrep/deg042
  16. Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013;28:1077-83. https://doi.org/10.1093/humrep/det015
  17. Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I. Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol 2007;23:486-93. https://doi.org/10.1080/09513590701532815
  18. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357-62. https://doi.org/10.1016/S0015-0282(01)02993-4
  19. Shim AR, Hwang YI, Lim KJ, Choi YM, Jeon YE, Seo SK, et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome: the relationship with clinical, hormonal and metabolic characteristics. Korean J Obstet Gynecol 2011;54:659-65. https://doi.org/10.5468/KJOG.2011.54.11.659
  20. Wiser A, Shehata F, Holzer H, Hyman JH, Shalom-Paz E, Son WY, et al. Effect of high LH/FSH ratio on women with polycystic ovary syndrome undergoing in vitro maturation treatment. J Reprod Med 2013;58:219-23.
  21. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815-30.
  22. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008;23:1924-31. https://doi.org/10.1093/humrep/den239
  23. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries: a common finding in normal women. Lancet 1988;1:870-2.
  24. Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005;234:81-6. https://doi.org/10.1016/j.mce.2004.09.008
  25. Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H. Elevated serum levels of anti-Mullerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstet Gynecol Scand 2013;92:1369-74. https://doi.org/10.1111/aogs.12247
  26. You SY, Park SY, Yang GY, Jeong KA, Kim YJ, Chung HW. Anti-Mullerian hormone in women with polycystic ovary syndrome. Korean J Obstet Gynecol 2012;55:315-24. https://doi.org/10.5468/KJOG.2012.55.5.315
  27. Kubota T. Update in polycystic ovary syndrome: new criteria of diagnosis and treatment in Japan. Reprod Med Biol 2013;12:71-7. https://doi.org/10.1007/s12522-013-0145-1
  28. Hsu MI, Liou TH, Liang SJ, Su HW, Wu CH, Hsu CS. Inappropriate gonadotropin secretion in polycystic ovary syndrome. Fertil Steril 2009;91:1168-74. https://doi.org/10.1016/j.fertnstert.2008.01.036
  29. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728-33.
  30. Turhan NO, Toppare MF, Seckin NC, Dilmen G. The predictive power of endocrine tests for the diagnosis of polycystic ovaries in women with oligoamenorrhea. Gynecol Obstet Invest 1999;48:183-6. https://doi.org/10.1159/000010170
  31. Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem 2006;43:217-9. https://doi.org/10.1258/000456306776865188
  32. Sikka P, Gainder S, Dhaliwal LK, Bagga R, Sialy R, Sahdev S. Ultrasonography of the ovaries and its correlation with clinical and endocrine parameters in infertile women with PCOS. Int J Fertil Womens Med 2007;52:41-7.
  33. Kyei-Mensah AA, LinTan S, Zaidi J, Jacobs HS. Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome. Hum Reprod 1998;13:1437-41. https://doi.org/10.1093/humrep/13.6.1437
  34. Dewailly D, Robert Y, Helin I, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, et al. Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol (Oxf) 1994;41:557-62. https://doi.org/10.1111/j.1365-2265.1994.tb01818.x

피인용 문헌

  1. Ultrasound features of polycystic ovaries relate to degree of reproductive and metabolic disturbance in polycystic ovary syndrome vol.103, pp.3, 2014, https://doi.org/10.1016/j.fertnstert.2014.12.094
  2. It’s Never over until It’s over: How Can Age and Ovarian Reserve Be Mathematically Bound through the Measurement of Serum AMH—A Study of 5069 Romanian Women vol.10, pp.4, 2014, https://doi.org/10.1371/journal.pone.0125216
  3. 1-h Postprandial glucose level is related to the serum anti-Müllerian hormone level in women with polycystic ovary syndrome vol.31, pp.10, 2014, https://doi.org/10.3109/09513590.2015.1056143
  4. Follicle-stimulating hormone associates with prediabetes and diabetes in postmenopausal women vol.53, pp.2, 2014, https://doi.org/10.1007/s00592-015-0769-1
  5. Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers vol.2016, pp.None, 2016, https://doi.org/10.1155/2016/5246217
  6. Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes vol.32, pp.2, 2014, https://doi.org/10.3109/09513590.2015.1107895
  7. Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center vol.60, pp.5, 2014, https://doi.org/10.1590/2359-3997000000215
  8. Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters vol.33, pp.9, 2017, https://doi.org/10.1080/09513590.2017.1310838
  9. Outcome and predictor of laparoscopic ovarian drilling for polycystic ovary syndrome vol.33, pp.2, 2014, https://doi.org/10.5180/jsgoe.33.2_129
  10. Comparative Evaluation of Diagnostic Efficacy of Serum Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome vol.10, pp.2, 2018, https://doi.org/10.5005/jp-journals-10006-1569
  11. Anti-Müllerian hormone level is associated with vitamin D receptor polymorphisms in women with polycystic ovary syndrome vol.36, pp.6, 2014, https://doi.org/10.1007/s10815-019-01472-3
  12. Inter-ovarian differences in ultrasound markers of ovarian size in women with polycystic ovary syndrome vol.46, pp.4, 2014, https://doi.org/10.5653/cerm.2019.00374
  13. Relationship between early follicular serum estrone level and other hormonal or ultrasonographic parameters in women with polycystic ovary syndrome vol.36, pp.2, 2014, https://doi.org/10.1080/09513590.2019.1633296
  14. Relevance of KISS1 gene polymorphisms in susceptibility to polycystic ovary syndrome and its associated endocrine and metabolic disturbances vol.77, pp.4, 2014, https://doi.org/10.1080/09674845.2020.1726662
  15. Influence of KISS1 gene polymorphisms on the risk of polycystic ovary syndrome and its associated variables, in Saudi women vol.20, pp.1, 2014, https://doi.org/10.1186/s12902-020-0537-2